Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-05-12 00:00:00 ET · period of report 2023-05-10 · accession 0001104659-23-059680 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-12 | 2023-05-10 | LGND | Sabba Stephen L | Dir | S - Sale+OE | $77.13 | -6,408 | 25.8K | -20% | -$494.2K |
| D | 2023-05-12 | 2023-05-10 | LGND | Sabba Stephen L | Dir | M - OptEx | $0.00 | +6,408 | 32.2K | +25% | $0 |
| D | 2023-05-12 | 2023-05-10 | LGND | Sabba Stephen L | Dir | M - OptEx | $0.00 | -6,408 | 927 | -87% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-10 | S | D | 6,408 | $77.13 | 25,784 | D | — | — | (F1) These securities, as represented in Column 5, include a grant of 1,723 restricted shares approved by the Board of Directors of the Company at the 2022 Meeting ("2022 Shares"), which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. As reported on the Reporting Person's Form 4 dated 14 June 2022, which was filed to reflect the 2022 Meeting grant, the original grant was for 1,004 2022 Shares. The reference to 1,732 2022 Shares reflects certain adjustments by the Company to the 2022 Shares following the Company's 1 November 2022 distribution of a legacy business. (F2) The price reported in Column 4 is an average. These shares were sold in separate transactions for the following number of shares and at the respective prices: $77.29 (100), $77.25 (8), $77.23 (41), $77.22 (36), $77.21 (201), $77.20 (372), $77.18 (800), $77.17 (120), $77.16 (34), $77.15 (971), $77.14 (1,305), $77.13 (151), $77.12 (1), $77.11 (239), $77.10 (101), $77.09 (100), $77.08 (1,065), $77.01 (9), and $77.00 (754). This disposition was reported on a Form 144 for filed 10 May 2023. |
| 2 | Common | Common Stock | 2023-05-10 | M | A | 6,408 | $0.00 | 32,192 | D | — | — | (F1) These securities, as represented in Column 5, include a grant of 1,723 restricted shares approved by the Board of Directors of the Company at the 2022 Meeting ("2022 Shares"), which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. As reported on the Reporting Person's Form 4 dated 14 June 2022, which was filed to reflect the 2022 Meeting grant, the original grant was for 1,004 2022 Shares. The reference to 1,732 2022 Shares reflects certain adjustments by the Company to the 2022 Shares following the Company's 1 November 2022 distribution of a legacy business. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-05-10 | M | D | 6,408 | $0.00 | 927 | D | $18.82 · — to 2023-06-11 | 6,408 Common Stock | (F3) These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2013 Meeting, as previously reported on the Reporting Persons Form 4 dated 13 June 2013. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. |